Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 23Head and Neck Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Squamous Cell 8Neoplasms 7Lung Neoplasms 7Colonic Neoplasms 7Rectal Neoplasms 6Esophageal Neoplasms 5Carcinoma 5Recurrence 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Neoplasms, Squamous Cell 3Hereditary Sensory and Autonomic Neuropathies 3Glioblastoma 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Cancer Metastatic 3Breast Neoplasms 3Tongue Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Melanoma 2Glioma 2

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2sintilimab 2osimertinib 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2Carboplatin 2zimberelimab 1ulocuplumab 1sotorasib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × Cetuximab × Clear all
NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Recruiting
542 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡